Literature DB >> 6802081

Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience.

F Speerstra, A M Boerbooms, L B van de Putte, H J van Beusekom, M W Kruijsen, J P Vandenbroucke.   

Abstract

Our experience with azathioprine in the treatment of rheumatoid arthritis covers ten years, during which 91 rheumatoid patients (66 female and 25 male) received this drug, with a median treatment period of 36 months. Total follow-up experience, during and after treatment, was 399 person years. Twelve patients died. The principal causes of death were malignant neoplasm (six patients) and cardiovascular diseases (three patients). The mortality in our patients was compared to that of the general Dutch population by the Standardised Mortality Ratio (SMR). In the male patient group a significant excess of both total mortality and mortality from malignancy was observed. The female patients showed no differences from the general population. In this follow-up study, no lymphoreticular tumours occurred during or after azathioprine therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802081      PMCID: PMC1030293          DOI: 10.1136/ard.41.suppl_1.37

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.

Authors:  James D Lewis; Oren Abramson; Monina Pascua; Liyan Liu; Laura M Asakura; Fernando S Velayos; Susan M Hutfless; James E Alison; Lisa J Herrinton
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-22       Impact factor: 11.382

2.  Association between azathioprine therapy and lymphoma in rheumatoid disease.

Authors:  P I Pitt; A H Sultan; M Malone; V Andrews; E B Hamilton
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

3.  Methotrexate and rheumatoid arthritis.

Authors:  A M Boerbooms
Journal:  Clin Rheumatol       Date:  1985-12       Impact factor: 2.980

4.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; L Brandt; E Baecklund; L Bertilsson; N Feltelius; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

5.  Purine enzyme activities in recent onset rheumatoid arthritis: are there differences between patients and healthy controls?

Authors:  J N Stolk; A M Boerbooms; R A De Abreu; P J Kerstens; D G de Koning; R de Graaf; J Mulder; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

Review 6.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.